PAF (C16)ligand for PAF receptors CAS# 74389-68-7 |
- Raltitrexed
Catalog No.:BCC4457
CAS No.:112887-68-0
- Nelarabine
Catalog No.:BCC1072
CAS No.:121032-29-9
- Lomustine
Catalog No.:BCC4794
CAS No.:13010-47-4
- ABT-751 (E7010)
Catalog No.:BCC1085
CAS No.:141430-65-1
- Isotretinoin
Catalog No.:BCC2284
CAS No.:4759-48-2
- CYT997 (Lexibulin)
Catalog No.:BCC4601
CAS No.:917111-44-5
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 74389-68-7 | SDF | Download SDF |
| PubChem ID | 108156 | Appearance | Powder |
| Formula | C26H54NO7P | M.Wt | 523.68 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | Platelet-activating factor | ||
| Solubility | Soluble to 100 mM in water and to 100 mM in ethanol | ||
| Chemical Name | [(2R)-2-acetyloxy-3-hexadecoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate | ||
| SMILES | CCCCCCCCCCCCCCCCOCC(COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)C | ||
| Standard InChIKey | HVAUUPRFYPCOCA-AREMUKBSSA-N | ||
| Standard InChI | InChI=1S/C26H54NO7P/c1-6-7-8-9-10-11-12-13-14-15-16-17-18-19-21-31-23-26(34-25(2)28)24-33-35(29,30)32-22-20-27(3,4)5/h26H,6-24H2,1-5H3/t26-/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Endogenous platelet-activating factor (PAF) and ligand for PAF receptors. Produced by inflammatory cells and a potent chemoattractant for polymorphonuclear neutrophils. Induces increased vascular permeability. |
PAF (C16) Dilution Calculator
PAF (C16) Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.9096 mL | 9.5478 mL | 19.0956 mL | 38.1913 mL | 47.7391 mL |
| 5 mM | 0.3819 mL | 1.9096 mL | 3.8191 mL | 7.6383 mL | 9.5478 mL |
| 10 mM | 0.191 mL | 0.9548 mL | 1.9096 mL | 3.8191 mL | 4.7739 mL |
| 50 mM | 0.0382 mL | 0.191 mL | 0.3819 mL | 0.7638 mL | 0.9548 mL |
| 100 mM | 0.0191 mL | 0.0955 mL | 0.191 mL | 0.3819 mL | 0.4774 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
PAF (C16) is an endogenous platelet-activating factor (PAF) and ligand for PAF receptors.
The platelet-activating factor receptor is a G-protein coupled receptor which binds platelet-activating factor.
PAF is produced by inflammatory cells and polymorphonuclear neutrophils. It induces increased vascular permeability. To examine the loss of selective endothelial permeability, the extravasative effect of PAF was assessed by monitoring the plasma loss of 125I-albumin (6.7 nm), 125I-low density lipoproteins (22.0 nm) and 125I-very low density lipoproteins (62.1 nm). There was no selective plasma retention of the labeled plasma tracers, which suggest that PAF-induced extravasation is dose-dependent, with increases in vascular permeability [1].
Given into the renal arterial circulation of male Wistar rats, PAF (C16) increased in renal blood flow (6-15%) in a dose-dependent way. The PAF-induced systemic hypotension and renal vasodilation are independent of renal innervation and are PAF-receptor mediated [2].
References:
[1]. Handley DA, Arbeeny CM, Lee ML, et al. Effect of platelet activating factor on endothelial permeability to plasma macromolecules. Immunopharmacology, 1984, 8(3-4): 137-142.
[2]. Handa RK, Strandhoy JW, Buckalew VM Jr. Platelet-activating factor is a renal vasodilator in the anesthetized rat. Am J Physiol, 1990, 258(6 Pt 2): F1504-1509.
- Leuprolide Acetate
Catalog No.:BCC1701
CAS No.:74381-53-6
- 8-Geranyloxypsoralen
Catalog No.:BCN4296
CAS No.:7437-55-0
- 4-hydroxyephedrine hydrochloride
Catalog No.:BCC8103
CAS No.:7437-54-9
- Ent-16Α,17-Dihydroxy-19-Kauranoic Acid
Catalog No.:BCC9227
CAS No.:74365-74-5
- Chidamide
Catalog No.:BCC6445
CAS No.:743420-02-2
- (RS)-AMPA
Catalog No.:BCC6560
CAS No.:74341-63-2
- 4',4'''-Di-O-methylcupressuflavone
Catalog No.:BCN4295
CAS No.:74336-91-7
- Schisandrin A
Catalog No.:BCN5815
CAS No.:7432-28-2
- Z-Trp-OH
Catalog No.:BCC2750
CAS No.:7432-21-5
- Somatostatin 1-28
Catalog No.:BCC5715
CAS No.:74315-46-1
- Quercetin-3-gentiobioside
Catalog No.:BCN3878
CAS No.:7431-83-6
- Sinapine thiocyanate
Catalog No.:BCN2765
CAS No.:7431-77-8
- Symlandine
Catalog No.:BCN1974
CAS No.:74410-74-5
- Sauvagine
Catalog No.:BCC5792
CAS No.:74434-59-6
- Potassium Chloride
Catalog No.:BCC7581
CAS No.:7447-40-7
- Casegravol
Catalog No.:BCN4591
CAS No.:74474-76-3
- Alprostadil
Catalog No.:BCC4963
CAS No.:745-65-3
- MMAF
Catalog No.:BCC5144
CAS No.:745017-94-1
- Ivachtin
Catalog No.:BCC2357
CAS No.:745046-84-8
- UBP 296
Catalog No.:BCC7255
CAS No.:745055-86-1
- UBP 302
Catalog No.:BCC7256
CAS No.:745055-91-8
- Cristacarpin
Catalog No.:BCN3935
CAS No.:74515-47-2
- Isomedicarpin
Catalog No.:BCN4297
CAS No.:74560-05-7
- D-64131
Catalog No.:BCC1510
CAS No.:74588-78-6
Vasorelaxant effect of C16-PAF and C18-PAF on renal blood flow and systemic blood pressure in the anesthetized rat.[Pubmed:1875784]
Life Sci. 1991;49(10):747-52.
The renal vasoactive and systemic hypotensive effects of platelet activating factor (C16:0-PAF and C18:1-PAF) were examined in anesthetized male Wistar rats. Bolus injections of C16-PAF (0.5-25 ng/kg) and C18-PAF (2.5-200 ng/kg) into the arterial circulation of the kidney produced increases in renal blood flow (6-15%) before causing dose-dependent systemic hypotension (2-64 mmHg). The dose-response curves for renal blood flow and systemic blood pressure generated by intrarenal C18-PAF administration were approximately 7 fold to the right of the dose-response curves generated by C16-DPAF. Intrarenal injections of vehicle or the biologically inactive enantiomer C16-DPAF (25-200 ng/kg) did not affect renal blood flow or systemic blood pressure. These results suggest that C16:0-PAF is a more potent renal vasodilator and hypotensive lipid than C18:1-PAF.
Actions of platelet activating factor (PAF) homologues and their combinations on neutrophil chemokinesis and cutaneous inflammatory responses in man.[Pubmed:3385217]
J Invest Dermatol. 1988 Jul;91(1):82-5.
The inflammatory actions of synthetic C16:0 and C18:0 platelet activating factor (PAF) homologues, both alone and in combination, have been compared in an in vitro human neutrophil chemokinesis assay and by intradermal injection in human skin. In the chemokinesis assay, the maximum distance moved by neutrophils in the presence of C18:0 PAF was significantly greater than that seen with the C16:0 compound. A mixture of C16:0 and C18:0 PAFs in a ratio of 1:9 appeared to be more active than in a ratio of 3:1. Intradermal injection of the C16:0 and C18:0 PAF homologues induced dose-dependent increases in weal volume and flare area responses which were not significantly different. Combination of these phospholipids in a ratio of 3:1 or 1:9 of C16:0:C18:0 did not significantly alter the dose response curves. Thus, changes in the chain length of the alkyl substituent of synthetic PAF homologues and combination of these homologues, in ratios found in vivo or formed by leukocytes in vitro, did not alter the cutaneous inflammatory responses to PAF in man. The C18:0 homologue was, however, more active as a human neutrophil chemoattractant in vitro.
Molecular species of platelet-activating factor generated by human neutrophils challenged with ionophore A23187.[Pubmed:3917470]
J Immunol. 1985 Feb;134(2):1090-3.
Two species of platelet-activating factor (PAF), 1-hexadecyl- and 1-octadecyl-2-acetyl-sn-glycero-3-phosphocholine (C16 = 0 AGEPC and C18 = 0 AGEPC) were detected in ionophore A23187-stimulated human neutrophils. The amount of AGEPC in 1 x 10(7) neutrophil cells was 80 +/- 26 pmol (mean +/- standard error) with a range of 14 to 223 pmol (n = 8), and it consisted of 80% of the C16 = 0 species and 20% of the C18 = 0 species. Most of the AGEPC derived from ionophore-treated neutrophils remained cell associated rather than being secreted into the medium, even when the medium contained ample albumin protein, which can trap AGEPC. These results were obtained by a technique of gas chromatography-mass spectrometry coupled with selected ion monitoring.
